RESUMEN
Radiation therapy (RT) in combination with immune checkpoint inhibitor (ICI) represents a promising regimen for non-small cell lung cancer (NSCLC), however, the underlying mechanisms are poorly characterized. We identified a specific dose of RT that conferred tumor regression and improved survival in NSCLC models when combined with ICI. The immune-modulating functions of RT was ascribed to activated lung-resident Scgb1a1+ club cells. Importantly, mice with club cell-specific knockout of synaptosome-associated protein 23 failed to benefit from the combination treatment, indicating a pivotal role of club cell secretome. We identified 8 club cells secretory proteins, which inhibited immunosuppressive myeloid cells, reduced pro-tumor inflammation, and enhanced anti-tumor immunity. Notably, CC10, a member of club cell secretome was increased in plasma of NSCLC patients responding to the combination therapy. By revealing an immune-regulatory role of club cells, our studies have the potential to guide future clinical trials of ICI in NSCLC.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Animales , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Humanos , Inhibidores de Puntos de Control Inmunológico/farmacología , Neoplasias Pulmonares/tratamiento farmacológico , Ratones , Uteroglobina/uso terapéuticoRESUMEN
OBJECTIVES: To evaluate the dose effects of Recombinant human Club cell 10-kDa protein (rhCC10) on lung function in a well-characterized ovine model of acute respiratory distress syndrome (ARDS) induced by smoke inhalation injury (SII); specifically, the potential of rhCC10 protein to control the inflammatory response and protect pulmonary tissue and function following SII. DESIGN: Randomized, controlled, prospective, and large animal translational studies. SETTING: University large animal intensive care unit. SUBJECTS: Thirty-six adult female sheep were surgically prepared and allocated into five groups (Sham (no SII), nâ=â6; 1âmg/kg/d CC10, nâ=â8; 3âmg/kg/d CC10, nâ=â7; 10âmg/kg/d CC10, nâ=â8; Control SII, nâ=â7). INTERVENTIONS: All groups except the sham group were subjected to SII with cooled cotton smoke. Then, the animals were placed on a ventilator, treated with 1, 3, and 10âmg/kg/d of intravenous rhCC10 or vehicle, divided evenly into two administrations per day every 12âh, fluid resuscitated, and monitored for 48âh in a conscious state. MEASUREMENTS AND MAIN RESULTS: The group treated with 10âmg/kg/d rhCC10 attenuated changes in the following variables: PaO2/FiO2 ratio, oxygenation index, and peak inspiratory pressure; neutrophil content in the airway and myeloperoxidase levels; obstruction of the large and small airways; systemic leakage of fluid and proteins, and pulmonary edema. CONCLUSIONS: In this study, high-dose rhCC10 significantly attenuated ARDS progression and lung dysfunction and significantly reduced systemic extravasation of fluid and proteins, normalizing fluid balance. Based on these results, rhCC10 may be considered a novel therapeutic option for the treatment of SII-induced ARDS.
Asunto(s)
Síndrome de Dificultad Respiratoria/prevención & control , Lesión por Inhalación de Humo/complicaciones , Uteroglobina/uso terapéutico , Animales , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Edema Pulmonar/etiología , Edema Pulmonar/prevención & control , Proteínas Recombinantes , Síndrome de Dificultad Respiratoria/etiología , OvinosRESUMEN
BACKGROUND: Preterm neonates can develop chronic pulmonary insufficiency of prematurity (CPIP) later in infancy. Recombinant human CC10 protein (rhCC10) is an anti-inflammatory agent that could potentially prevent CPIP. METHODS: The safety and efficacy of a single intratracheal dose of rhCC10 in reducing CPIP at 12 months corrected gestational age (CGA) was evaluated in a Phase II double-blind, randomized, placebo-controlled, multisite clinical trial. Eighty-eight neonates were randomized: 22 to placebo and 22 to 1.5 mg/kg rhCC10 in the first cohort and 21 to placebo and 23 to 5 mg/kg rhCC10 in the second cohort. Neonates were followed to 12 months CGA. RESULTS: With CPIP defined as signs/symptoms, medical visits, hospital readmissions, and use of medications for respiratory complications at 12 months CGA, no significant differences were observed between rhCC10 or placebo groups. Only 5% of neonates had no evidence of CPIP at 12 months CGA. CONCLUSIONS: A single dose of rhCC10 was not effective in reducing CPIP at 12 CGA. Since most neonates had evidence of CPIP using these exploratory endpoints, it is essential to develop more robust outcome measures for clinical trials of respiratory medications in high-risk premature neonates.
Asunto(s)
Enfermedades Pulmonares/tratamiento farmacológico , Síndrome de Dificultad Respiratoria del Recién Nacido/tratamiento farmacológico , Uteroglobina/uso terapéutico , Antiinflamatorios/uso terapéutico , Enfermedad Crónica , Método Doble Ciego , Femenino , Predisposición Genética a la Enfermedad , Edad Gestacional , Humanos , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro , Pulmón/efectos de los fármacos , Masculino , Readmisión del Paciente , Seguridad del Paciente , Surfactantes Pulmonares/administración & dosificación , Proteínas Recombinantes/uso terapéutico , Respiración , Factores de Riesgo , Resultado del TratamientoRESUMEN
BACKGROUND: Antiflammin-1 (AF-1), a derivative of uteroglobin (UG), is a synthetic nonapeptide with diverse biological functions. In the present study, we investigated whether AF-1 has a protective effect against bleomycin-induced pulmonary fibrosis. METHODS: C57BL/6 mice were injected with bleomycin intratracheally to create an animal model of bleomycin-induced pulmonary fibrosis. On Day 7 and Day 28, we examined the anti-inflammatory effect and antifibrotic effect, respectively, of AF-1 on the bleomycin-treated mice. The effects of AF-1 on the transforming growth factor-beta 1 (TGF-ß1)-induced proliferation of murine lung fibroblasts (NIH3T3) were examined by a bromodeoxycytidine (BrdU) incorporation assay and cell cycle analysis. RESULTS: Severe lung inflammation and fibrosis were observed in the bleomycin-treated mice on Day 7 and Day 28, respectively. Administration of AF-1 significantly reduced the number of neutrophils in the bronchoalveolar lavage fluid (BALF) and the levels of tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1ß) in the lung homogenates on Day 7. Histological examination revealed that AF-1 markedly reduced the number of infiltrating cells on Day 7 and attenuated the collagen deposition and destruction of lung architecture on Day 28. The hydroxyproline (HYP) content was significantly decreased in the AF-1-treated mice. In vitro, AF-1 inhibited the TGF-ß1-induced proliferation of NIH3T3 cells, which was mediated by the UG receptor. CONCLUSIONS: AF-1 has anti-inflammatory and antifibrotic actions in bleomycin-induced lung injury. We propose that the antifibrotic effect of AF-1 might be related to its suppression of fibroblast growth in bleomycin-treated lungs and that AF-1 has potential as a new therapeutic tool for pulmonary fibrosis.
Asunto(s)
Antiinflamatorios/uso terapéutico , Bleomicina/efectos adversos , Fragmentos de Péptidos/uso terapéutico , Fibrosis Pulmonar/inducido químicamente , Fibrosis Pulmonar/prevención & control , Uteroglobina/uso terapéutico , Animales , Antiinflamatorios/farmacología , Proliferación Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Fibroblastos/efectos de los fármacos , Hidroxiprolina/metabolismo , Técnicas In Vitro , Interleucina-1beta/metabolismo , Pulmón/metabolismo , Pulmón/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Células 3T3 NIH , Fragmentos de Péptidos/farmacología , Fibrosis Pulmonar/metabolismo , Factor de Crecimiento Transformador beta1/farmacología , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/metabolismo , Uteroglobina/farmacologíaRESUMEN
Asthma is a chronic airway inflammatory disease characterized by eosinophilic infiltration and airway hyperresponsiveness. The over-activated Th2 and lung epithelium cells express many different cytokines, and chemokines mainly contribute to the severity of lung inflammation. Clara cell 10 kD protein (CC10) is highly expressed in airway epithelium cells and exhibits anti-inflammatory and immunomodulatory effects. Adeno-associated virus (AAV) 2/9 vector, composed of AAV2 rep and AAV9 cap genes, can efficiently and specifically target lung epithelium cells. Thus, AAV2/9 vector might carry therapeutic potential gene sequences for the treatment of asthma. This study tested whether AAV2/9 vector carrying CC10 could reduce inflammatory and asthmatic responses in OVA-induced asthmatic mouse model. The results showed that AAV2/9-CC10 vector virus significantly reduced airway hyperresponsiveness, CCL11, interleukin (IL)-4, IL-5, IL-6, IL-13, and eosinophilia in the lungs of sensitized mice. CC10 level in OVA-sensitized mice was rescued with the administration of AAV2/9-CC10 vector virus. Lung tissue remodeling, including collagen deposition and goblet cell hyperplasia, was also alleviated. However, serum levels of OVA-specific IgG1 and IgE as well as Th2 cytokine levels in OVA-stimulated splenocyte culture supernatants were at the comparable levels to the sensitized control group. The results demonstrate that AAV2/9-CC10 vector virus relieved local inflammatory and asthmatic responses in lung. Therefore, we propose that AAV2/9-CC10 vector virus guaranteed sufficient CC10 expression and had an anti-inflammatory effect in asthmatic mice. It might be applied as a novel therapeutic approach for asthma.
Asunto(s)
Asma/fisiopatología , Asma/terapia , Terapia Genética/métodos , Vectores Genéticos/uso terapéutico , Uteroglobina/uso terapéutico , Animales , Asma/inducido químicamente , Hiperreactividad Bronquial/terapia , Líquido del Lavado Bronquioalveolar/química , Cartilla de ADN/genética , Dependovirus , Inmunoglobulina E/sangre , Inmunoglobulina G/sangre , Inmunohistoquímica , Interleucinas/sangre , Pulmón/patología , Ratones , Células 3T3 NIH , Ovalbúmina/toxicidad , Resultado del TratamientoRESUMEN
BACKGROUND: The Clara cell 10 (CC10) protein is produced by the airway epithelium. Reduced levels of CC10 are associated with allergic rhinitis and asthma. In experimental models, treatment with the CC10 protein may reduce features of airway inflammation. OBJECTIVES: To examine whether or not topical treatment with recombinant human CC10 (rhCC10) affects symptoms and signs of allergic rhinitis in a pollen season model. METHODS: Out of the pollen season, patients with allergic rhinitis received treatment with rhCC10, 0.56 mg per nasal cavity, once daily for 7 days in a double-blinded, placebo-controlled, crossover design. During this period, individualized allergen challenges were given once daily. Symptoms and peak nasal inspiratory flow (PNIF) were recorded daily in the morning, 10 minutes after challenge, and in the evening. Mean recordings of the last 3 days of the challenge series were used in the analysis. Nasal lavages were performed at the end of each challenge period, and eosinophil cationic protein, myeloperoxidase, and alpha2-macroglobulin levels were measured as indices of eosinophil and neutrophil activity and plasma exudation, respectively. RESULTS: Recombinant human CC10 did not affect allergen-induced morning, postchallenge, or evening symptoms compared with placebo. Morning, postchallenge, and evening PNIF were not improved by rhCC10. No statistically significant differences were observed between rhCC10 and placebo for any of the lavage fluid indices. CONCLUSIONS: Repeated nasal administrations of rhCC10 protein, in the present dose, do not exert antiallergic effects in seasonal allergic rhinitis.
Asunto(s)
Polen/inmunología , Proteínas Recombinantes/uso terapéutico , Rinitis Alérgica Estacional/tratamiento farmacológico , Uteroglobina/uso terapéutico , Administración Intranasal , Adulto , Alérgenos/inmunología , Alérgenos/farmacología , Estudios de Casos y Controles , Estudios Cruzados , Método Doble Ciego , Proteína Catiónica del Eosinófilo/análisis , Proteína Catiónica del Eosinófilo/inmunología , Humanos , Macroglobulinas/análisis , Macroglobulinas/inmunología , Masculino , Persona de Mediana Edad , Lavado Nasal (Proceso) , Nariz/inmunología , Peroxidasa/análisis , Peroxidasa/inmunología , Proteínas Recombinantes/administración & dosificación , Rinitis Alérgica Estacional/inmunología , Uteroglobina/administración & dosificaciónRESUMEN
Complications from meconium aspiration syndrome (MAS) remain significant despite a variety of therapeutic interventions. Clara cell protein (CC10) is a novel anti-inflammatory agent that can also inhibit phospholipase A2 (PLA2) (an important component of meconium). The present study examined whether administration of recombinant human CC10 (rhCC10) would reduce inflammation and improve lung function in a piglet model of MAS. Following meconium instillation, piglets exhibited significant physiologic dysfunction that improved significantly after surfactant administration. Analysis of tracheal aspirates revealed significant increases in both tumor necrosis factor (TNF) alpha and interleukin (IL)-8 after meconium instillation. rhCC10-treated animals had significantly lower TNF-alpha levels at 24 h (561 +/- 321 versus 1357 +/- 675 pg/mL, p < 0.05) compared with saline controls. There were no differences between rhCC10-treated and untreated groups with respect to other measured physiologic variables or inflammatory markers, including secretory PLA2 activity. Histologic analyses revealed marked inflammatory infiltrates and thickened alveolar walls, but no significant differences among rhCC10 and control animals. Newborn piglets with MAS have significant physiologic dysfunction, marked inflammatory changes and histologic abnormalities, which was partially counteracted by a single dose of exogenous surfactant and rhCC10.
Asunto(s)
Antiinflamatorios/farmacología , Pulmón/efectos de los fármacos , Síndrome de Aspiración de Meconio/tratamiento farmacológico , Uteroglobina/farmacología , Animales , Animales Recién Nacidos , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/citología , Modelos Animales de Enfermedad , Quimioterapia Combinada , Inhibidores Enzimáticos/farmacología , Humanos , Recién Nacido , Interleucina-8/sangre , Interleucina-8/metabolismo , Pulmón/enzimología , Pulmón/metabolismo , Pulmón/patología , Pulmón/fisiopatología , Meconio/metabolismo , Síndrome de Aspiración de Meconio/metabolismo , Síndrome de Aspiración de Meconio/patología , Síndrome de Aspiración de Meconio/fisiopatología , Fosfolipasas A2 Secretoras/antagonistas & inhibidores , Fosfolipasas A2 Secretoras/metabolismo , Surfactantes Pulmonares/farmacología , Proteínas Recombinantes/farmacología , Porcinos , Factores de Tiempo , Factor de Necrosis Tumoral alfa/sangre , Factor de Necrosis Tumoral alfa/metabolismo , Uteroglobina/administración & dosificación , Uteroglobina/uso terapéuticoRESUMEN
OBJECTIVE: To test the hypothesis that recombinant Clara cell secretory protein (rhCC10) instillation would foster improved lung function, acute structural preservation, and attenuation of matrix metalloproteinase (MMP) activity in a surfactant-deficient, mechanically ventilated lung. DESIGN: Interventional laboratory study. SETTING: An academic medical research facility in the northeastern United States. SUBJECTS: Sedated, ventilated premature lambs. INTERVENTIONS: Preterm lambs (n = 18; 126 +/- 3 days gestation) were instrumented, ventilated, and treated with 100 mg/kg exogenous surfactant. Lambs were randomized to receive 0, 0.5, or 5.0 mg/kg rhCC10 (n = 6 per group) and were ventilated for 4 hrs. MEASUREMENTS AND MAIN RESULTS: Posttreatment, lung function and cardiopulmonary stability were monitored for the ventilation period and then animals were killed for in vitro surfactant function analysis, lung histomorphometry, and analysis of MMP-2, -7, and -9 as well as their tissue inhibitors (TIMP)-1 and -2. Ventilation efficiency and pulmonary compliance were improved in the 5.0-mg/kg rhCC10 group by 4 hrs. Lung expansion was variable in the apical regions only. MMP-2 quantity was greater in the apical than the base lung regions of rhCC10-treated groups, and rhCC10 decreased MMP-7 in the base of the lung. CONCLUSIONS: These data suggest that improved lung function in the surfactant-treated preterm lamb following intratracheal rhCC10 may be related to the reduction of proteolytic activity of MMP-7.
Asunto(s)
Inhibidores Enzimáticos/uso terapéutico , Metaloproteasas/metabolismo , Respiración Artificial , Síndrome de Dificultad Respiratoria del Recién Nacido/terapia , Uteroglobina/uso terapéutico , Animales , Animales Recién Nacidos , Modelos Animales de Enfermedad , Inhibidores Enzimáticos/administración & dosificación , Humanos , Recién Nacido , Pulmón/patología , Rendimiento Pulmonar , Metaloproteasas/antagonistas & inhibidores , Inhibidores de Proteasas/análisis , Alveolos Pulmonares/patología , Surfactantes Pulmonares/uso terapéutico , Síndrome de Dificultad Respiratoria del Recién Nacido/tratamiento farmacológico , Síndrome de Dificultad Respiratoria del Recién Nacido/enzimología , Síndrome de Dificultad Respiratoria del Recién Nacido/patología , Ovinos , Factores de Tiempo , Inhibidor Tisular de Metaloproteinasa-1/análisis , Inhibidor Tisular de Metaloproteinasa-2/análisis , Resultado del Tratamiento , Uteroglobina/administración & dosificaciónRESUMEN
OBJECTIVE: To test the hypothesis that intratracheal instillation of Clara cell secretory protein (CC 10) to the lung may afford greater protection than intravenous administration from ventilator-induced lung inflammation. DESIGN: Interventional laboratory study. SETTING: An academic medical research facility in northeastern United States. SUBJECTS: Sedated, lavage-injured juvenile rabbits. INTERVENTIONS: A total of 18 juvenile rabbits were anesthetized, ventilated, injured with saline lavage (Pao2 of <100 mm Hg; respiratory compliance of <0.50 mL.cm H2O.kg and <50% baseline), and randomized to receive intratracheally administered surfactant plus no recombinant human CC 10 (rhCC 10, control), intravenous rhCC 10, or intratracheal rhCC 10. MEASUREMENT AND MAIN RESULTS: Arterial blood chemistry and pulmonary mechanics were monitored; plasma and urine were collected serially. After 4 hrs of ventilation, lungs were lavaged and harvested. Surfactant function was analyzed from bronchoalveolar lavage samples (surfactometry); rhCC 10, interleukin-8, and lung myeloperoxidase concentrations were measured. Pao2, oxygenation index, ventilatory efficiency index, and respiratory compliance were not different across time or group beyond injury. Surfactometry data identified no differences as a function of group or time. Plasma, bronchoalveolar lavage, and lung interleukin-8 concentrations, lung myeloperoxidase concentrations, and inflammatory cell counts in the alveolar and interstitial spaces of intravenous and intratracheal groups were lower than in the control group (p < .05) but not statistically different from each other. Concentrations of rhCC 10 in lung, bronchoalveolar lavage, and plasma were greater in the intratracheal group than in the intravenous group (p<.05). Urine rhCC 10 concentrations were greater for the intravenous group than for the intratracheal group (p<.05) at 1, 3, and 4 hrs after treatment. No group differences in histomorphometry were noted. CONCLUSIONS: Both intravenous and intratracheal rhCC 10 delivery, after surfactant therapy, effectively decrease lung inflammation vs. surfactant alone. While supporting the physiologic profile, intratracheal instillation results in greater, maintained lung and plasma rhCC 10 pools compared with intravenous administration. As such, intratracheal instillation of rhCC 10 may afford more prolonged protection against lung inflammation than intravenous administration.
Asunto(s)
Respiración Artificial/efectos adversos , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Uteroglobina/administración & dosificación , Animales , Líquido del Lavado Bronquioalveolar/citología , Modelos Animales de Enfermedad , Vías de Administración de Medicamentos , Mediadores de Inflamación/antagonistas & inhibidores , Conejos , Distribución Aleatoria , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/uso terapéutico , Síndrome de Dificultad Respiratoria/etiología , Síndrome de Dificultad Respiratoria/inmunología , Uteroglobina/uso terapéuticoRESUMEN
BACKGROUND: A novel breast cancer-associated antigen, mammaglobin-A, is expressed in 80% of primary breast tumors. The characterization of immune responses against this highly expressed breast cancer-specific antigen would be of value in the development of new therapeutic strategies for breast cancer. METHODS: We developed an in vivo model using human leukocyte antigen-A*0201/human CD8+ (HLA-A2+/hCD8+) double-transgenic mice to define the epitopes and to study the level of protection acquired by mammaglobin-A cDNA vaccination toward mammaglobin-A+/HLA-A2+ breast cancer cell lines. Mammaglobin-A epitopes were identified using an HLA class I peptide binding prediction computer program, and their activity was verified using gamma interferon ELISPOT and cytotoxicity assays. RESULTS: We identified seven mammaglobin-A-derived candidate epitopes that bind the HLA-A*0201 molecule (Mam-A2.1-7). CD8+ cytotoxic T lymphocytes (CTLs) from HLA-A2+/hCD8+ mice reacted to the Mam-A2.1 (amino acids [aa] 83-92, LIYDSSLCDL), Mam-A2.2 (aa 2-10, KLLMVLMLA), Mam-A2.4 (aa 66-74, FLNQTDETL), and Mam-A2.6 (aa 32-40, MQLIYDSSL) epitopes. CD8+ CTLs from breast cancer patients also recognized a similar epitope pattern as did those in the HLA-A2+/hCD8 mice and reacted to the Mam-A2.1, Mam-A2.2, Mam-A2.3, Mam-A2.4, and Mam-A2.7 epitopes. Passive transfer of mammaglobin-A-reactive CTLs into SCID (severe combined immunodeficient) beige mice with actively growing mammaglobin-A+ tumors resulted in statistically significant regression (P<.001) in the growth of the tumors. CONCLUSIONS: The HLA-A2+/hCD8+ mouse represents a valuable animal model to characterize the HLA-A*0201-restricted CD8+ CTL immune response to mammaglobin-A in vivo, and the data reported here demonstrate the immunotherapeutic potential of mammaglobin-A for the treatment and/or prevention of breast cancer.
Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/inmunología , Vacunas contra el Cáncer/farmacología , Inmunoterapia/métodos , Proteínas de Neoplasias/farmacología , Uteroglobina/farmacología , Animales , Linfocitos T CD8-positivos/inmunología , Vacunas contra el Cáncer/uso terapéutico , ADN Complementario/uso terapéutico , Modelos Animales de Enfermedad , Epítopos , Femenino , Humanos , Mamoglobina A , Ratones , Ratones Transgénicos , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/uso terapéutico , Linfocitos T Citotóxicos/inmunología , Uteroglobina/genética , Uteroglobina/uso terapéuticoRESUMEN
Currently, there are very few diagnostic or therapeutic strategies targeted at controlling tumor growth and progression towards metastasis. Uteroglobin (UG) is a naturally occurring, small, stable, secretory protein that is normally expressed by most cells of epithelial origin but is known to be lost during the progression of prostate, lung, and uterine cancers to invasive malignancy. Uteroglobin -/- knockout mice appear to be extremely cancer prone. Both pharmacological and transgenic reconstitution of recombinant human UG (rhUG) to prostate, lung, and endometrial tumor cell lines markedly inhibits their invasiveness and antagonizes the neoplastic phenotype. In preliminary studies, rhUG inhibited angiogenesis in the ex vivo rat aorta model and showed antitumor activity against human prostate tumor cells (PC-3) in the chick chorioallantoic membrane assay, reducing both tumor volume and vascularity. A recent in vivo pilot study showed that twice daily dosing with rhUG resulted in a statistically significant increase in survival without evidence of toxicity in severe combined immunodeficient mice challenged with a PC-3 cell metastasizing tumor. Thus, rhUG may slow the progression of cancer by inhibiting both tumor cell invasiveness and tumor angiogenesis. It therefore holds the potential to serve as a new weapon in the arsenal of cytostatic, antimetastatic, adjuvant treatment for cancer. In this paper, we will briefly discuss the therapeutic potential of uteroglobin-based strategies for managing prostate cancer.
Asunto(s)
Neoplasias de la Próstata/genética , Neoplasias de la Próstata/terapia , Uteroglobina/genética , Uteroglobina/uso terapéutico , Animales , Biopsia con Aguja , Embrión de Pollo , Modelos Animales de Enfermedad , Regulación Neoplásica de la Expresión Génica , Genes Supresores de Tumor , Humanos , Inmunohistoquímica , Masculino , Ratones , Ratones Transgénicos , Proyectos Piloto , Pronóstico , Neoplasias de la Próstata/mortalidad , Neoplasias de la Próstata/patología , Ratas , Sensibilidad y Especificidad , Tasa de Supervivencia , Células Tumorales Cultivadas , Uteroglobina/metabolismoRESUMEN
The anti-inflammatory action of nonapeptide fragments of uteroglobin or lipocortin I known as antiflammins, was tested in the carrageenan or phospholipase A2 rat paw oedema model. The development of carrageenan-induced oedema in rats was significantly inhibited during the early and late phases of the oedema by the local administration of antiflammins 1 and 2. However, the peptides were not able to inhibit phospholipase A2-induced oedema. The time course of the anti-oedematous activity of nonapeptides after intradermal carrageenan injection may be attributed to their effect on mast cell degranulation and accumulation and activation of leukocytes. Naja naja phospholipase A2 exhibited strong histamine release-inducing activity, which may have contributed to the rat paw oedema induction. Surprisingly, antiflammins had a limited but significant inhibitory effect on histamine secretion.